Recently Featured

Evotec Appoints AI Expert Ashiq Khan as Chief Commercial Officer to Drive Transformation

April 4, 2026
Evotec has appointed Ashiq Khan, Ph.D., as chief commercial officer, signaling a strategic pivot as the company embarks on a comprehensive transformation plan. Khan’s extensive background in robotics and artificial intelligence positions him uniquely to lead the commercial team, which is critical to the company’s future growth and innovation initiatives. This appointment comes at a…

Phage Chemical “Crosstalk” Can Backfire, Steering Responders Into Lysogeny

April 4, 2026
Recent research from the University of Exeter reveals that bacteriophages can manipulate each other’s life-cycle decisions through a chemical messaging system known as arbitrium. This study, published in Cell, demonstrates that signals intended to guide phage behavior can inadvertently mislead competitors into premature dormancy, thereby altering the competitive dynamics within shared bacterial environments. Bacteriophages face…

Lilly Acquires Centessa for Up to $7.8B; Biogen Buys Apellis for Up to $6.1B

April 4, 2026
Eli Lilly has announced its agreement to acquire Centessa Pharmaceuticals for up to $7.8 billion, while Biogen is set to purchase Apellis Pharmaceuticals for approximately $6.1 billion. These transactions highlight a significant trend in the pharmaceutical industry towards consolidation, particularly in the realms of neurology and immunology. Centessa, based in the U.K. and Boston, is…

Recessive Neurodevelopmental Disorder Identified Is the Most Prevalent Ever Discovered

April 4, 2026
Researchers at the Icahn School of Medicine at Mount Sinai have unveiled a previously unidentified recessive neurodevelopmental disorder (NDD) linked to the gene RNU2-2, which is projected to affect thousands in the U.S. and account for approximately 10% of known recessive NDD cases. This disorder arises from a near-total absence of U2-2 RNA, a small…

Ongoing Cases